Global Bladder Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 218 pages | ID: G221357BCA8EN
Precision Business Insights (PBI)

Abstracts

Global Bladder Cancer Treatment Market:

Global bladder cancer treatment market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for bladder cancer treatment is projected to reach US$ XX Mn by 2023.

Bladder cancer is a disease in which malignant cells are formed in the tissues of the bladder. Symptoms of bladder cancer include blood in the urine, pain with urination and low back pain. There are three types of bladder cancer that begin in the cells in the lining of the bladder. They are named as transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma.

Increase in incidence rate of bladder cancer cases, technological advancements, drug innovations with regard to the treatment of bladder cancer, government initiatives, the rise in aging of the population, and advanced health care services are expected to drive the market for bladder cancer treatment drugs. In addition, the rise in awareness about bladder diseases, their available therapies in the market, and increase in health care expenditure are driving the global market for bladder cancer treatment drugs. However, the rise in a number of patent expirations, asymptomatic nature of the disease, and rise in the use of generic drugs are some of the major factors restraining the revenue growth of the global bladder cancer treatment drugs market over the forecast period.

Global bladder cancer treatment market is segmented based on cancer type, drug class, and distribution channel:

Based on cancer type, global bladder cancer treatment market is segmented as:

• Transitional cell bladder cancer
• Invasive bladder cancer
• Superficial bladder cancer
• Squamous cell bladder cancer
• Other rare types

Based on drug class, global bladder cancer treatment market is segmented as:

• Chemotherapy
• Alkylating agents
• Plant alkaloids
• Taxanes
• Anti-tumour Antibiotics
• Anti-metabolites
• Topoisomerase inhibitors
• Immunotherapy
• Tumor-targeting mAbs
• DC-Based immunotherapy
• Peptide- and DNA-based anticancer vaccines
• Immune stimulatory cytokines
• Immune modulatory mAbs
• Immuno suppressive metabolism Inhibitors
• Pattern recognition receptor Agonists
• Others

Based on distribution channel, global bladder cancer treatment market is segmented as:

• Hospital Pharmacies
• Retail Pharmacies
• Others

As per to the National Institute of Health, approximately17,000 women and 45,000 men for every year are diagnosed with the bladder cancer in U.S. only. Market for bladder cancer is rapidly increasing and it is anticipated to grow rapidly from 2016 to 2022 globally. As per to The American Cancer Society, in 2017, estimated bladder cancers in the United States were 79,030 new cases (about 60,490 in men and 18,540 in women) were diagnosed and about 16,870 deaths from bladder cancer (about 12,240 in men and 4,630 in women).Bladder cancer accounts for about 5% of all new cancers in the US. It is the fourth most common cancer in men, but it is less common in women. In addition, the rise in awareness about bladder cancer and its available treatment options in the market, innovation in drug development, and subsequent technological advancements are expected to drive the market for bladder cancer treatment drugs. Increasing number of mergers and acquisitions, the rise in a number of collaborations and partnerships, new product launches and growing awareness about the availability of bladder cancer treatment drugs are some of the latest trends that have been observed in the market.

Global bladder cancer treatment market is segmented into five regions: North America, Europe, Asia Pacific, Latin America and The Middle East & Africa. North America followed by Europe, comprise largest market share for the bladder cancer treatment market due to the availability of advanced health care solutions, increase in the bladder cancer cases, rise in concern about bladder problems and development of health care infrastructure in the region. Asia is expected to show a high growth rate in the bladder cancer treatment drugs market during the forecast period due to rise in significant growth in bladder cancer cases, rise in need for the improved bladder cancer treatments and therapies, increasing awareness on cancer diagnosis. Growing demographics and economies in the developing countries, such as India and China, are anticipated to rise the bladder cancer treatment drugs market in Asia-Pacific region.

Some of the players in the global bladder cancer treatment market include AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Co., F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Pfizer Inc.( U.S.), and Sanofi (France)

In 2017, AstraZeneca received U.S. FDA accelerated approval for Imfinzi (Durvalumab) for the treatment of bladder cancer

In 2016, FDA has granted Biologic License Application and priority review of Roche’s Atezolizumab for the treatment of advanced bladder cancer

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL BLADDER CANCER TREATMENT MARKET INTRODUCTION

2.1. Global Bladder Cancer Treatment Market– Taxonomy
2.2. Global Bladder Cancer Treatment Market–Definitions
  2.2.1. Drug Class
  2.2.2. Cancer Type

3. GLOBAL BLADDER CANCER TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Bladder Cancer Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Bladder Cancer Treatment Market– Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
3.7. Global Bladder Cancer Treatment Market– Recent Product Launches

4. GLOBAL BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL BLADDER CANCER TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Chemotherapeutic Agents (Alkylating agents, Plant alkaloids, Taxanes, Anti-tumour Antibiotics, Anti-metabolites, and Topoisomerase inhibitors)
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Immunotherapy (Tumor-targeting mAbs, DC-Based immunotherapy, Peptide- and DNA-based anticancer vaccines, Immune stimulatory cytokines, Immun modulatory mAbs, and Others)
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis

6. GLOBAL BLADDER CANCER TREATMENT MARKET FORECAST, BY CANCER TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Transitional Cell Bladder Cancer
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Invasive Bladder Cancer
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Superficial Bladder Cancer
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Squamous Cell Bladder Cancer
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis
6.5. Other Rare Types
  6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.5.3. Market Opportunity Analysis

7. GLOBAL BLADDER CANCER TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Others
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL BLADDER CANCER TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Chemotherapy
      9.1.1.1.1. Alkylating agents
      9.1.1.1.2. Plant alkaloids
      9.1.1.1.3. Taxanes
      9.1.1.1.4. Anti-tumour Antibiotics
      9.1.1.1.5. Anti-metabolites
      9.1.1.1.6. Topoisomerase inhibitors
    9.1.1.2. Immunotherapy
      9.1.1.2.1. Tumor-targeting mAbs
      9.1.1.2.2. DC-Based immunotherapy
      9.1.1.2.3. Peptide- and DNA-based anticancer vaccines
      9.1.1.2.4. Immune stimulatory cytokines
      9.1.1.2.5. Immune modulatory mAbs
      9.1.1.2.6. Immuno suppressive metabolism Inhibitors
      9.1.1.2.7. Pattern recognition receptor Agonists
      9.1.1.2.8. Others
  9.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Transitional cell bladder cancer
    9.1.2.2. Invasive bladder cancer
    9.1.2.3. Superficial bladder cancer
    9.1.2.4. Squamous cell bladder cancer
    9.1.2.5. Other rare types
  9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Hospital Pharmacies
    9.1.3.2. Retail Pharmacies
    9.1.3.3. Others
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
  9.1.6. North America Bladder Cancer Treatment Market Dynamics – Trends

10. EUROPE BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Chemotherapy
      10.1.1.1.1. Alkylating agents
      10.1.1.1.2. Plant alkaloids
      10.1.1.1.3. Taxanes
      10.1.1.1.4. Anti-tumour Antibiotics
      10.1.1.1.5. Anti-metabolites
      10.1.1.1.6. Topoisomerase inhibitors
    10.1.1.2. Immunotherapy
      10.1.1.2.1. Tumor-targeting mAbs
      10.1.1.2.2. DC-Based immunotherapy
      10.1.1.2.3. Peptide- and DNA-based anticancer vaccines
      10.1.1.2.4. Immune stimulatory cytokines
      10.1.1.2.5. Immune modulatory mAbs
      10.1.1.2.6. Immuno suppressive metabolism Inhibitors
      10.1.1.2.7. Pattern recognition receptor Agonists
      10.1.1.2.8. Others
  10.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Transitional cell bladder cancer
    10.1.2.2. Invasive bladder cancer
    10.1.2.3. Superficial bladder cancer
    10.1.2.4. Squamous cell bladder cancer
    10.1.2.5. Other rare types
  10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Hospital Pharmacies
    10.1.3.2. Retail Pharmacies
    10.1.3.3. Others
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
  10.1.6. Europe Bladder Cancer Treatment Market Dynamics – Trends

11. ASIA-PACIFIC BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Chemotherapy
      11.1.1.1.1. Alkylating agents
      11.1.1.1.2. Plant alkaloids
      11.1.1.1.3. Taxanes
      11.1.1.1.4. Anti-tumour Antibiotics
      11.1.1.1.5. Anti-metabolites
      11.1.1.1.6. Topoisomerase inhibitors
    11.1.1.2. Immunotherapy
      11.1.1.2.1. Tumor-targeting mAbs
      11.1.1.2.2. DC-Based immunotherapy
      11.1.1.2.3. Peptide- and DNA-based anticancer vaccines
      11.1.1.2.4. Immune stimulatory cytokines
      11.1.1.2.5. Immune modulatory mAbs
      11.1.1.2.6. Immuno suppressive metabolism Inhibitors
      11.1.1.2.7. Pattern recognition receptor Agonists
      11.1.1.2.8. Others
  11.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Transitional cell bladder cancer
    11.1.2.2. Invasive bladder cancer
    11.1.2.3. Superficial bladder cancer
    11.1.2.4. Squamous cell bladder cancer
    11.1.2.5. Other rare types
  11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Hospital Pharmacies
    11.1.3.2. Retail Pharmacies
    11.1.3.3. Others
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
  11.1.6. Asia-Pacific Bladder Cancer Treatment Market Dynamics – Trends

12. LATIN AMERICA BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Chemotherapy
      12.1.1.1.1. Alkylating agents
      12.1.1.1.2. Plant alkaloids
      12.1.1.1.3. Taxanes
      12.1.1.1.4. Anti-tumour Antibiotics
      12.1.1.1.5. Anti-metabolites
      12.1.1.1.6. Topoisomerase inhibitors
    12.1.1.2. Immunotherapy
      12.1.1.2.1. Tumor-targeting mAbs
      12.1.1.2.2. DC-Based immunotherapy
      12.1.1.2.3. Peptide- and DNA-based anticancer vaccines
      12.1.1.2.4. Immune stimulatory cytokines
      12.1.1.2.5. Immune modulatory mAbs
      12.1.1.2.6. Immuno suppressive metabolism Inhibitors
      12.1.1.2.7. Pattern recognition receptor Agonists
      12.1.1.2.8. Others
  12.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Transitional cell bladder cancer
    12.1.2.2. Invasive bladder cancer
    12.1.2.3. Superficial bladder cancer
    12.1.2.4. Squamous cell bladder cancer
    12.1.2.5. Other rare types
  12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Hospital Pharmacies
    12.1.3.2. Retail Pharmacies
    12.1.3.3. Others
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
  12.1.6. Latin America Bladder Cancer Treatment Market Dynamics – Trends

13. MIDDLE EAST & AFRICA BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Chemotherapy
      13.1.1.1.1. Alkylating agents
      13.1.1.1.2. Plant alkaloids
      13.1.1.1.3. Taxanes
      13.1.1.1.4. Anti-tumour Antibiotics
      13.1.1.1.5. Anti-metabolites
      13.1.1.1.6. Topoisomerase inhibitors
    13.1.1.2. Immunotherapy
      13.1.1.2.1. Tumor-targeting mAbs
      13.1.1.2.2. DC-Based immunotherapy
      13.1.1.2.3. Peptide- and DNA-based anticancer vaccines
      13.1.1.2.4. Immune stimulatory cytokines
      13.1.1.2.5. Immune modulatory mAbs
      13.1.1.2.6. Immuno suppressive metabolism Inhibitors
      13.1.1.2.7. Pattern recognition receptor Agonists
      13.1.1.2.8. Others
  13.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Transitional cell bladder cancer
    13.1.2.2. Invasive bladder cancer
    13.1.2.3. Superficial bladder cancer
    13.1.2.4. Squamous cell bladder cancer
    13.1.2.5. Other rare types
  13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Hospital Pharmacies
    13.1.3.2. Retail Pharmacies
    13.1.3.3. Others
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
  13.1.6. MEA Bladder Cancer Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. AstraZeneca plc (U.K.)
  14.2.2. Bristol-Myers Squibb (U.S.)
  14.2.3. Celgene Corporation (U.S.)
  14.2.4. Eli Lilly and Company (U.S.)
  14.2.5. F. Hoffmann-La Roche (Switzerland)
  14.2.6. GlaxoSmithKline plc (U.K.)
  14.2.7. Novartis AG (Switzerland)
  14.2.8. Pfizer Inc. (U.S.)
  14.2.9. Sanofi (France)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS